SCHEMBL8965058

SCHEMBL8965058

Cc1cc(O)cc(O)c1C(=O)c1ccccc1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 5/20 0.63
ACHE P22303 2/20 0.63
LMNA P02545 3/20 0.61
MEN1 O00255 5/20 0.53
KMT2A Q03164 5/20 0.53
GAA P10253 2/20 0.53
USP2 O75604 1/20 0.53
KEAP1 Q14145 1/20 0.53
NFE2L2 Q16236 1/20 0.53
TDP1 Q9NUW8 2/20 0.50
SMN1; SMN2 Q16637 2/20 0.50
BCL2L1 Q07817 1/20 0.50
ALDH1A1 P00352 3/20 0.49
HPGD P15428 3/20 0.49
MAPK1 P28482 2/20 0.49
ALOX15 P16050 1/20 0.49
HSD17B10 Q99714 1/20 0.49
FASN P49327 1/20 0.48
CYP1A2 P05177 1/20 0.46
PGR P06401 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL353943 0.86 FASN (0.64) CYP3A4ACHELMNAMEN1KMT2A
SCHEMBL11482949 0.85 KMT2A (0.50) CYP3A4ACHELMNAMEN1KMT2A
SCHEMBL7766611 0.84 CYP3A4 (0.72) CYP3A4ACHELMNAMEN1KMT2A
SCHEMBL28689599 0.83 CYP3A4 (0.61) CYP3A4LMNAMEN1KMT2AGAA
SCHEMBL12081977 0.82 CYP3A4 (0.55) CYP3A4ACHELMNAMEN1KMT2A
SCHEMBL8619002 0.81 BCL2L1 (0.54) CYP3A4ACHELMNAMEN1KMT2A
SCHEMBL11590335 0.80 CYP3A4 (0.79) CYP3A4ACHELMNAMEN1KMT2A
Orsellinic Acid SCHEMBL522294 0.78 CYP3A4 (1.00) CYP3A4ACHELMNAMEN1KMT2A
SCHEMBL28515130 0.78 BCL2L1 (0.50) CYP3A4LMNAMEN1KMT2AGAA
SCHEMBL22658267 0.77 SYNJ2 (0.69) CYP3A4LMNAMEN1KMT2AGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160367521-A1 XANTHONE-RICH PLANT EXTRACTS OR COMPOUNDS THEREFROM FOR MODULATING DISEASES OF THE CENTRAL NERVOUS SYSTEM AND RELATED DISORDERS DEAKIN UNIVERSITY (AU) 2016-12-22 US disclosed
US-5518851-A BINDER, FLASH LIGHT FIXING FUJITSU LIMITED (JP) 1996-05-21 US disclosed
EP-0463822-B1 Toner FUJITSU LTD (JP) 1996-03-13 EP disclosed
US-5389485-A Void resistance, good fixability; for flash light fixing apparatus FUJITSU LIMITED (JP) 1995-02-14 US disclosed
EP-0463822-A2 Toner FUJITSU LIMITED (JP) 1992-01-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160367521-A1 XANTHONE-RICH PLANT EXTRACTS OR COMPOUNDS THEREFROM FOR MODULATING DISEASES OF THE CENTRAL NERVOUS SYSTEM AND RELATED DISORDERS GAP43, PMP22, ACHE CYP3A4 4057/4885ACHE 3/4885LMNA 647/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.